Nasal ACE2 Levels and COVID-19 in Children
Open Access
- 16 June 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 323 (23), 2386-2387
- https://doi.org/10.1001/jama.2020.8946
Abstract
Coronavirus disease 2019 (COVID-19) has disproportionately affected certain vulnerable populations. Studies noted higher rates of certain comorbidities such asThis publication has 15 references indexed in Scilit:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and AdolescentsJAMA Pediatrics, 2020
- Spread of SARS-CoV-2 in the Icelandic PopulationThe New England Journal of Medicine, 2020
- Variation in COVID-19 Hospitalizations and Deaths Across New York City BoroughsJAMA, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort studyThe Lancet Infectious Diseases, 2020
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2Cell, 2020
- SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genesNature Medicine, 2020
- Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005